Immunogenicity of the Xcl1-SARS-CoV-2 Spike Fusion DNA Vaccine for COVID-19

SARS-CoV-2 spike (S) variants that may evade antibody-mediated immunity are emerging. Evidence shows that vaccines with a stronger immune response are still effective against mutant strains. Here, we report a targeted type 1 conventional dendritic (cDC1) cell strategy for improved COVID-19 vaccine d...

Descripción completa

Detalles Bibliográficos
Autores principales: Qi, Hailong, Sun, Zhongjie, Yao, Yanling, Chen, Ligong, Su, Xuncheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8951015/
https://www.ncbi.nlm.nih.gov/pubmed/35335039
http://dx.doi.org/10.3390/vaccines10030407

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8951015/
https://www.ncbi.nlm.nih.gov/pubmed/35335039
http://dx.doi.org/10.3390/vaccines10030407

Ejemplares similares